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Paget's Disease (Osteitis Deformans) 
Background 
1. Definition  
o Metabolic bone disease characterized by accelerated bone resorption and 
formation, resulting in bone that is less organized and more susceptible to 
deformity and fracture 
2. General info  
o Unknown etiology 
o Viral and genetic factors have been implied 
 
Pathophysiology  
1. Pathology of disease  
o Affected osteoclasts increase in both size and number causing increased rate 
of bone resorption 
o In response, osteoblasts form bone in a more rapid and less organized 
manner, resulting in a mosaic pattern 
2. Incidence/prevalence  
o 1-3% of adults >40 yo 
o Incidence increases with age 
3. Risk factors  
o Higher prevalence in western Europe (UK, Germany and France) and 
populations that have immigrated to Australia, North and South America, 
New Zealand, and South Africa 
4. Morbidity/mortality  
o 70% asymptomatic (most cases discovered incidentally) 
o Fractures are most common 
o Deafness 
o Tumors 
o Bone deformities 
 
Diagnostics 
1. History  
o Symptomatic patients will often present with deep, aching bone pain, even at 
rest 
o Paget's in the skull can cause narrowing of foramina, resulting in hearing 
loss, cranial nerve palsies, and risk of brainstem compression 
2. Physical examination  
o Skeletal deformities  
 Bowing of lower extremities 
 Frontal bossing 
o Increased warmth over affected area 
3. Diagnostic testing  
o Labs  
 Elevated total serum alkaline phosphatase 
 Vitamin D levels to rule out deficiency 
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 Serum calcium to rule out hyperparathyroidism  
 Normal in Paget's 
 Urinary deoxypyridinoline and N-telopeptide of type I collagen are less 
reliable and more expensive 
o Imaging  
 Radiographs  
 Active sites often have an osteolytic front (classically 'blade of 
grass' lesion) 
 Long bones will show cortical thickening and sclerotic changes 
 Bone Scans  
 Most sensitive in detecting sites of active lesions, but are less 
specific 
 CT and MRI can help differentiate between malignant and Paget's bone 
 Biopsy is definitive 
 
Differential Diagnosis 
1. Osteosarcoma  
o Tendency to be located in metaphysis of long bones 
o Imaging  
 X-ray: sunburst sign (spiculated periosteal reaction) 
 X-ray: periosteal formation at edge of soft tissue 
o Core needle Bx for definitive Dx 
2. Hyperparathyroidism (Osteitis fibrosa cystica)  
o PE  
 Proximal muscle weakness 
 Bone pain 
 Brisk stretch reflexes of muscles 
o Labs  
 Elevated serum Ca/ alkaline phosphatase 
 Elevated PTH (severe) 
o Imaging  
 "Salt-and-pepper" appearance of calvarium 
 Brown's "tumors" (collections of osteoclasts, causing lytic lesions in 
long bones and pelvis) 
 Resorption of terminal phalanges, distal clavicles 
3. Osteomalacia (Vitamin D deficiency)  
o Low serum 25(OH)2D or low 1,25(OH)2D levels 
o Hypophosphatemia 
o Increase in alkaline phosphatase 
o Pathologic fracture  
 Fracture associated with abnormalities as stated herein 
4. Traumatic fracture  
o History of trauma 
o Absence of serum markers 
o Absence of characteristics on X-ray for classic Paget's or cancer  
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5. Osteoporosis  
o Testing to r/o secondary osteoporosis  
 PTHrP (parathyroid hormone related protein) – associated with 
humoral malignancy 
 Elevated PTH (parathyroid hormone) – hyperparathyroid, associated 
with hypercalcemia 
 Malignancy (bone mets) – depressed PTH 
o Bone density scanning for classifying severity of disease 
 
Therapeutics 
1. Initiation of treatment  
o Literature suggests treating the following patients (SOR:B)  
 Symptomatic 
 Asymptomatic with biochemical markers suggestive of bone 
remodeling (Serum Alkaline Phosphatase or SALP 125-150% above 
normal) 
o Patients with active lesions in weight bearing limbs or near major joints 
2. Bisphosphonates  
o Mainstay of treatment of Paget's is to normalize SALP (serum alkaline 
phosphatase) (SOR:A)  
o Oral  
 Alendronate 40 mg/d for 6 months  
 Normalization of SALP in 63% of patients in US trial 
 Retreatment when normal or nadir levels rise >25% 
 Risedronate 30 mg/d for 2 months  
 Normalization of SALP in 73% in US trial 
 Retreatment indications same as for Alendronate 
 Etidronate 400 mg/d for 6 months, with at least 6 month interval before 
retreatment  
 Normalization of SALP in 15% 
 Tiludronate 400 mg/d for 3 months  
 Normalization of SALP in 35% of patients 
o IV  
 Pamidronate 30-90 mg given over 2-3 hour infusion  
 For mild disease, single 60-90 mg dose is commonly used 
 For more advanced disease, 1-2 infusions per week on 
nonconsecutive days of 90 mg can be given up to 180-360 mg  
o Normal SALP in approximately 50% of patients 
o Fever, flu-like symptoms are most common adverse affects, 
seen after the first dose 
 Zoledronic acid  
 Currently in consideration for FDA approval 
 5 mg, 15 minute infusion 
 Normal SALP in up to 89% 6 months after treatment 
 Adverse effects similar to pamidronate 
3. Calcitonin  
o Salmon calcitonin given 100 U daily for several months  
 Normalization of SALP in approximately 50% of patients 
 Use of calcitonin has decreased due to efficacy of bisphosphonates 
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Follow up 
1. Office  
o Every 6-12 months in asymptomatic patients, or in treated stable patients to 
follow serum alkaline phosphate levels 
o Lifetime follow up (rare chance of osteosarcoma) 
o Earlier follow up with recurrence of symptoms 
2. Specialist referral  
o Complex or non-union fractures should be referred to orthopedics 
 
Prognosis (SOR:B)  
1. Paget's disease is a relatively benign condition with the majority of patients 
asymptomatic  
o Exceptions are bone pain, deformity, and possible fracture in weight bearing 
bones 
2. The majority of patients treated for elevated SALP achieve a normal level, but this 
has not been shown to change prognosis 
3. Left untreated, osteolytic changes can extend and bone deformities are more likely 
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